Inspired by the successful television series, the UCL School of Pharmacy has organised this clever and well-attended event where UCL scientists presented their small molecule therapeutics idea to a panel of seasoned pharma experts and investors, in front of a public of scientists and company representatives. We couldn’t resist the temptation to pitch our Virology Research Services, and although VRS is not quite a small molecule, it was clearly exciting enough to win the third prize from the public! Thank you!
Recents Posts
Five Questions to Ask Before Starting an Antiviral Study
Starting an antiviral programme is exciting. Whether you are developing a novel antiviral, validating a new platform technology, testing a disinfectant, or evaluating the neutralising activity of an antibody, the temptation is to jump straight to the experimental...
How to Choose the Right In Vitro Model for an Antiviral Study
Discussions on antiviral testing often focus on viral strains, compound administration, and assay parameters. Yet one of the most important decisions has already been made behind the scenes: selecting the most appropriate in vitro model. At VRS, our standard antiviral...
Influenza and Diabetes: Why Metabolic Health Matters in Viral Infection
Influenza is usually described as a respiratory virus, but its impact does not stop at the airways. For many people, flu is a short-lived illness of fever, cough, fatigue, and muscle aches. For others, particularly those with underlying metabolic disease, it can...
When it comes to viruses, we know our stuff!
Subscribe

